DK2002258T3 - Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme - Google Patents

Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme Download PDF

Info

Publication number
DK2002258T3
DK2002258T3 DK07753226.5T DK07753226T DK2002258T3 DK 2002258 T3 DK2002258 T3 DK 2002258T3 DK 07753226 T DK07753226 T DK 07753226T DK 2002258 T3 DK2002258 T3 DK 2002258T3
Authority
DK
Denmark
Prior art keywords
gelsolin
subject
multiple sclerosis
level
treating
Prior art date
Application number
DK07753226.5T
Other languages
English (en)
Inventor
Thomas P Stossel
Bonnie Dittel
Katarzyna Maresz
Po-Shun Lee
Original Assignee
Brigham & Womens Hospital Inc
Bloodcenter Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc, Bloodcenter Res Foundation Inc filed Critical Brigham & Womens Hospital Inc
Application granted granted Critical
Publication of DK2002258T3 publication Critical patent/DK2002258T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (10)

1. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, hvilken fremgangsmåde omfatter administration af gelsolin til individet flere gange.
2. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, ifølge krav 1, hvor individet ellers er fri for indikationer, der nødvendiggør behandling med gelsolin.
3. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, ifølge krav 1, hvor fremgangsmåden endvidere omfatter administration af et andet middel til behandling af multipel sklerose.
4. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, ifølge krav 3, hvor det andet middel er interferon (IFN)^lb (Betaseron eller Betaferon), IFN-pia (Avonex, Rebif), glatirameracetat (Copaxone), mitoxantron (Novantrone), azathioprin, cyclosporin, methotrexat, cyclophosphamid, intravenøst immunglobulin, prednison, methylprednison, prednisolon, methylprednisolon, dexamethason, adrenocorticotropt hormon (ACTH), corticotropin, 2-chlordeoxyadenosin (2-CDA, cladribin), inosin, interleukin-2-antistof (Zenapax, daclizumab), leucovorin, teriflunomid, estroprogestiner, desogestrel, etinilestradiol, BHT-3009, ABT-874, (Bacille Calmette-Guérin)-vaccine (BCG-vaccine), T-cellevaccination, CNTO 1275, Rituximab, Tysabri (natalizumab), N-acetylcystein, minocyclin, R00506997 eller et statin.
5. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, ifølge krav 1, hvor fremgangsmåden endvidere omfatter udvælgelse af et individ på det grundlag, at individet vides at have et niveau af gelsolin, som er mindst 10% mindre end det målte gennemsnitsniveau for en tilsyneladende rask population af individer; og administration af gelsolin til individet i en til behandling af individet, som har multipel sklerose, effektiv mængde.
6. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, ifølge krav 5 i kombination med et andet middel til behandling af multipel sklerose.
7. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, hvilken fremgangsmåde omfatter: (i) behandling af individet med en første behandling til behandling af multipel sklerose, (ii) opnåelse af et niveau af gelsolin hos individet, (iii) sammenligning af det i (ii) opnåede niveau af gelsolin med en forudbestemt værdi svarende til et forudbestemt niveau af gelsolin hos en tilsyneladende rask kontrolpopulation, og, hvis det forudbestemte niveau af gelsolin ikke er nået, (iv) behandling af individet med et andet middel til behandling af multipel sklerose, og gentagelse af (ii) og (iii), indtil det forudbestemte niveau af gelsolin er nået.
8. Fremgangsmåde til evaluering af virkningen af en behandling til behandling af eller reduktion af risikoen for multipel sklerose hos et individ, hvilken fremgangsmåde omfatter: (i) opnåelse in vitro af et niveau af gelsolin i blod, plasma eller serum fra et individ, som gennemgår behandling med et middel til behandling af multipel sklerose, (ii) sammenligning af det i (i) opnåede niveau af gelsolin med en forudbestemt værdi svarende til et forudbestemt niveau af gelsolin hos en tilsyneladende rask kontrolpopulation og (iii) bestemmelse af, om niveauet af gelsolin i (i) er på eller over det forudbestemte niveau, hvilken bestemmelse er indikativ for, om behandlingen er virkningsfuld.
9. Fremgangsmåde ifølge krav 8, hvor trin (i) og trin (ii) og/eller trin (iii) gentages for at monitorere individets niveauer af gelsolin over tid.
10. Fremgangsmåde ifølge krav 8, hvor midlet er gelsolin, interferon (IFN)-pib (Betaseron eller Betaferon), IFN-pia (Avonex, Rebif), glatirameracetat (Copaxone), mitoxantron (Novantrone), azathioprin, cyclosporin, methotrexat, cyclophosphamid, intravenøst immunglobulin, prednison, methylprednison, prednisolon, methylprednisolon, dexamethason, adrenocorticotropt hormon (ACTH), corticotropin, 2-chlordeoxyadenosin (2-CDA, cladribin), inosin, interleukin-2-antistof (Zenapax, daclizumab), leucovorin, teriflunomid, estroprogestiner, desogestrel, etinilestradiol, BHT-3009, ABT-874, (Bacille Calmette-Guérin)-vaccine (BCG-vaccine), T-cellevaccination, CNTO 1275, Rituximab, Tysabri (natalizumab), N-acetylcystein, minocyclin, R00506997 eller et statin.
DK07753226.5T 2006-03-15 2007-03-14 Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme DK2002258T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78250906P 2006-03-15 2006-03-15
PCT/US2007/006581 WO2007106577A2 (en) 2006-03-15 2007-03-14 Gelsolin in the treatment and diagnosis of neurological disease

Publications (1)

Publication Number Publication Date
DK2002258T3 true DK2002258T3 (da) 2018-01-02

Family

ID=38510104

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07753226.5T DK2002258T3 (da) 2006-03-15 2007-03-14 Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme

Country Status (11)

Country Link
US (2) US8440622B2 (da)
EP (1) EP2002258B1 (da)
JP (2) JP2009530613A (da)
CN (1) CN101460843B (da)
CA (1) CA2680333C (da)
DK (1) DK2002258T3 (da)
ES (1) ES2651619T3 (da)
HU (1) HUE035980T2 (da)
PL (1) PL2002258T3 (da)
PT (1) PT2002258T (da)
WO (1) WO2007106577A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1694342T3 (pl) * 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
PL1755661T3 (pl) 2004-05-12 2014-10-31 Brigham & Womens Hospital Inc Gelsolina do stosowania w leczeniu infekcji
JP4348631B2 (ja) * 2005-03-29 2009-10-21 セイコーエプソン株式会社 半導体素子の製造方法
PT3279663T (pt) 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
ES2634263T3 (es) 2008-01-25 2017-09-27 The General Hospital Corporation Usos de diagnóstico terapéuticos de gelsolina en insuficiencia renal
WO2009124226A2 (en) * 2008-04-03 2009-10-08 The Trustees Of The University Of Pennsylvania Gelsolin uses in neurological disorders
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
DE102010026500A1 (de) * 2010-07-07 2012-01-12 Arthrogen Gmbh Verfahren zur Herstellung von autologen Proteinen
EP3279668B1 (en) * 2010-12-16 2019-05-15 National Institute of Advanced Industrial Science and Technology Method for enrichment and separation of spinal fluid glycoprotein, method for searching for marker for central nervous system diseases which utilizes the aforementioned method, and marker for central nervous system diseases
KR101416954B1 (ko) 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
WO2015137738A1 (ko) * 2014-03-11 2015-09-17 한양대학교 산학협력단 혈액질환 진단
FR3036188B1 (fr) * 2015-05-12 2019-06-07 Biomerieux Prediction du risque de developper, pour des patients admis en service de reanimation, une infection disseminee
JP6947449B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
TWI697499B (zh) * 2018-03-05 2020-07-01 中央研究院 用以診斷周邊神經病變的方法及套組
EP4204818A1 (en) * 2020-09-23 2023-07-05 Bioaegis Therapeutics Inc. Compositions and methods for identifying and treating microparticle-associated diseases and conditions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627353A (en) * 1899-06-20 Cis robinson
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
AU663050B2 (en) 1990-04-11 1995-09-28 Brigham And Women's Hospital Therapeutic uses of actin-binding compounds
EP0481070A1 (en) 1990-05-04 1992-04-22 Biogen, Inc. Multimeric gelsolin fusion constructs
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5360350A (en) 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
US5691160A (en) 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5804427A (en) 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5925529A (en) 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
WO1998024465A1 (en) 1996-12-04 1998-06-11 The Victoria University Of Manchester Wound healing and treatment of fibrosis
ATE530180T1 (de) 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6409599B1 (en) 1999-07-19 2002-06-25 Ham On Rye Technologies, Inc. Interactive virtual reality performance theater entertainment system
AU2002225219A1 (en) 2001-01-26 2002-08-06 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
JP2006507270A (ja) 2002-02-06 2006-03-02 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 感染症および他の疾患の治療
WO2003088811A2 (en) 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
WO2004001421A2 (en) 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
CA2527916A1 (en) 2003-03-14 2004-09-30 Aaron B. Kantor Biological markers for diagnosing rheumatoid arthritis
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
PL1694342T3 (pl) 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
PL1755661T3 (pl) 2004-05-12 2014-10-31 Brigham & Womens Hospital Inc Gelsolina do stosowania w leczeniu infekcji
CN1993143A (zh) * 2004-06-04 2007-07-04 健泰科生物技术公司 用于治疗多发性硬化的方法
EP1929297B1 (en) * 2005-09-29 2012-11-21 Caprion Proteomics USA, LLC Biomarkers for multiple sclerosis and methods of use thereof
PT3279663T (pt) 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
ES2634263T3 (es) 2008-01-25 2017-09-27 The General Hospital Corporation Usos de diagnóstico terapéuticos de gelsolina en insuficiencia renal

Also Published As

Publication number Publication date
EP2002258B1 (en) 2017-09-27
EP2002258A2 (en) 2008-12-17
ES2651619T3 (es) 2018-01-29
WO2007106577A3 (en) 2008-10-16
JP2009530613A (ja) 2009-08-27
US8440622B2 (en) 2013-05-14
EP2002258A4 (en) 2009-03-18
CN101460843B (zh) 2018-06-22
US20100021428A1 (en) 2010-01-28
JP6203995B2 (ja) 2017-09-27
PT2002258T (pt) 2017-12-18
CA2680333C (en) 2016-10-25
PL2002258T3 (pl) 2018-06-29
HUE035980T2 (hu) 2018-06-28
CN101460843A (zh) 2009-06-17
WO2007106577A2 (en) 2007-09-20
US20130230455A1 (en) 2013-09-05
CA2680333A1 (en) 2007-09-20
JP2012053071A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
DK2002258T3 (da) Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme
EP2001496B1 (en) Use of gelsolin to diagnose and treat inflammatory diseases
EP2708603A1 (en) Diagnostic and therapeutic uses of gelsolin in renal failure
JP4837734B2 (ja) 痴呆及び神経炎症性疾患の検出のためのＣＳＦ検出ｉｎｖｉｔｒｏ方法
WO2016033187A1 (en) Use of gelsolin in the treatment and diagnosis of sickle cell disease
AU2013202205B2 (en) Use of Gelsolin to Diagnose and Treat Inflammatory Disease
Jobe Commentary on surfactant treatment of neonates with respiratory failure and group B streptococcal infection